Monte Total Current Liabilities vs Cash And Short Term Investments Analysis
| GLUE Stock | USD 9.11 0.51 5.93% |
Monte Rosa financial indicator trend analysis is infinitely more than just investigating Monte Rosa Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Monte Rosa Therapeutics is a good investment. Please check the relationship between Monte Rosa Total Current Liabilities and its Cash And Short Term Investments accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Total Current Liabilities vs Cash And Short Term Investments
Total Current Liabilities vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Monte Rosa Therapeutics Total Current Liabilities account and Cash And Short Term Investments. At this time, the significance of the direction appears to have strong relationship.
The correlation between Monte Rosa's Total Current Liabilities and Cash And Short Term Investments is 0.71. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Monte Rosa Therapeutics, assuming nothing else is changed. The correlation between historical values of Monte Rosa's Total Current Liabilities and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Monte Rosa Therapeutics are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Total Current Liabilities i.e., Monte Rosa's Total Current Liabilities and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | 0.71 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Total Current Liabilities
Total Current Liabilities is an item on Monte Rosa balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Monte Rosa Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Monte Rosa Therapeutics balance sheet. This account contains Monte Rosa investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Monte Rosa Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most indicators from Monte Rosa's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Monte Rosa Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. As of November 28, 2024, Selling General Administrative is expected to decline to about 17.5 M. In addition to that, Tax Provision is expected to decline to about 185.9 K
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.1M | 3.8M | 4.3M | 4.5M | Depreciation And Amortization | 2.1M | 8.6M | 6.2M | 3.9M |
Monte Rosa fundamental ratios Correlations
Click cells to compare fundamentals
Monte Rosa Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 0.221 | Return On Assets (0.28) | Return On Equity (0.61) |
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.